These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 30766825)

  • 1. Liraglutide - Indian Experience.
    Anirban M; Soumyabrata RC; Debmalya S; Bhattacharjee K
    Indian J Endocrinol Metab; 2018; 22(6):818-826. PubMed ID: 30766825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.
    Ostawal A; Mocevic E; Kragh N; Xu W
    Diabetes Ther; 2016 Sep; 7(3):411-38. PubMed ID: 27350545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting.
    Kaur P; Mahendru S; Mithal A
    Indian J Endocrinol Metab; 2016; 20(5):595-599. PubMed ID: 27730066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting.
    Kesavadev J; Shankar A; Krishnan G; Jothydev S
    Int J Gen Med; 2012; 5():317-22. PubMed ID: 22536087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India.
    Kaur P; Mishra SK; Mithal A; Saxena M; Makkar A; Sharma P
    Indian J Endocrinol Metab; 2014 Jan; 18(1):77-82. PubMed ID: 24701434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.
    Berkovic MC; Bilic-Curcic I; Herman Mahecic D; Gradiser M; Grgurevic M; Bozek T
    Diabetes Ther; 2017 Dec; 8(6):1297-1308. PubMed ID: 29076038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.
    Lorenzi M; Ploug UJ; Langer J; Skovgaard R; Zoratti M; Jansen J
    Diabetes Ther; 2017 Feb; 8(1):85-99. PubMed ID: 27995594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.
    Manigault KR; Thurston MM
    Consult Pharm; 2016 Dec; 31(12):685-697. PubMed ID: 28074747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.
    Feher M; Vega-Hernandez G; Mocevic E; Buysse B; Myland M; Power GS; Nystrup Husemoen LL; Kim J; Witte DR
    Diabetes Ther; 2017 Apr; 8(2):417-431. PubMed ID: 28281244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India.
    Wangnoo SK; Kumar S; Bhattacharyya A; Tripathi S; Akhtar S; Shetty R; Ghosal S
    Indian J Endocrinol Metab; 2016; 20(6):838-845. PubMed ID: 27867889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
    Langer J; Hunt B; Valentine WJ
    J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.
    Gomez-Peralta F; Lecube A; Fernández-Mariño A; Alonso Troncoso I; Morales C; Morales-Pérez FM; Guler I; Cadarso-Suárez C
    Diabet Med; 2018 Nov; 35(11):1605-1612. PubMed ID: 29943854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
    Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
    Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
    PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.
    Lind M; Matsson PO; Linder R; Svenningsson I; Jørgensen L; Ploug UJ; Gydesen H; Dorkhan M; Larsen S; Johansson G
    Diabetes Ther; 2016 Jun; 7(2):321-33. PubMed ID: 27216947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial.
    de Wit HM; Vervoort GM; Jansen HJ; de Galan BE; Tack CJ
    J Intern Med; 2016 Mar; 279(3):283-92. PubMed ID: 26553486
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.